YG 1805
Alternative Names: YG-1805Latest Information Update: 23 Jan 2023
At a glance
- Originator Youngene Therapeutics
- Class Antihyperglycaemics; Digestion aids; Gastrokinetics; Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Constipation; Diabetic nephropathies; Heart failure; Polycystic ovary syndrome
Most Recent Events
- 17 Jan 2023 Preclinical trials in Constipation in China (unspecified route) (Youngene Therapeutics pipeline, January 2023)
- 17 Jan 2023 Preclinical trials in Diabetic nephropathies in China (unspecified route) (Youngene Therapeutics pipeline, January 2023)
- 17 Jan 2023 Preclinical trials in Heart failure in China (unspecified route) (Youngene Therapeutics pipeline, January 2023)